Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE3.1700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4400/ 3
- Ask / Lots5.0700/ 1
- Open / Previous Close0.0000 / 3.1700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 502 | 3.26 |
| 09:36 ET | 998 | 3.21 |
| 09:38 ET | 100 | 3.3699 |
| 10:06 ET | 400 | 3.45 |
| 10:14 ET | 4172 | 3.0715 |
| 10:15 ET | 500 | 3.2574 |
| 10:19 ET | 1300 | 3.1 |
| 10:24 ET | 200 | 3.07 |
| 11:18 ET | 250 | 2.8054 |
| 11:29 ET | 170 | 2.9878 |
| 11:49 ET | 200 | 3.075 |
| 12:20 ET | 100 | 3.25 |
| 01:08 ET | 100 | 3.25 |
| 02:00 ET | 325 | 3.159 |
| 03:52 ET | 100 | 3.175 |
| 03:56 ET | 100 | 3.17 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 91.0M | -2.5x | --- |
Capricor Therapeutics Inc | 90.7M | -3.9x | --- |
Xilio Therapeutics Inc | 91.2M | -1.1x | --- |
Eliem Therapeutics Inc | 91.9M | -1.8x | --- |
Anixa Biosciences Inc | 91.4M | -5.8x | --- |
Galectin Therapeutics Inc | 87.9M | -2.6x | --- |
Company Information
Candel Therapeutics, Inc is a clinical stage biopharmaceutical company. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The Company also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman Of the Board
- Carrie Cox
- President, Chief Executive Officer, Director
- Paul Tak
- Founder, Chief Scientific Officer, Director
- Estuardo Aguilar-cordova
- Chief Financial Officer
- John Canepa
- Vice President - Head of Research
- Francesca Barone
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $91.0M |
|---|---|
Revenue (TTM) | $124.0K |
Shares Outstanding | 28.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.26 |
Book Value | $2.24 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 733.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -24,238.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
